Highly divergent type 2 and 3 vaccine-derived polioviruses isolated from Sewage in Tallinn, Estonia

Journal of Virology

Volumn 87, Issue 23, 2013, Pages 13076-13080

  Al Hello, Haider ^a   Jorba, Jaume ^c   Blomqvist, Soile ^a   Raud, Riina ^b   Kew, Olen ^c   Roivainen, Merja ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^b Health Protection Inspectorate   (Estonia)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

POLIOMYELITIS VACCINE;

AMINO ACID SUBSTITUTION; ARTICLE; COMMON VARIABLE IMMUNODEFICIENCY; CONTROLLED STUDY; ESTONIA; EXPRESSED SEQUENCE TAG; MONTE CARLO METHOD; MUTATION RATE; NONHUMAN; NUCLEOTIDE SEQUENCE; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; SEQUENCE ANALYSIS; SEQUENCE HOMOLOGY; SEROTYPE; SEWAGE; VACCINE DERIVED POLIOVIRUS 1; VACCINE DERIVED POLIOVIRUS 2; VIRUS CAPSID; VIRUS DETECTION; VIRUS IDENTIFICATION; VIRUS ISOLATION; VIRUS MUTATION; VIRUS RECOMBINATION; VIRUS STRAIN;

BASE SEQUENCE; CAPSID PROTEINS; ESTONIA; EVOLUTION, MOLECULAR; HUMANS; MOLECULAR SEQUENCE DATA; PHYLOGENY; POLIOMYELITIS; POLIOVIRUS; POLIOVIRUS VACCINES; RECOMBINATION, GENETIC; SEQUENCE ALIGNMENT; SEWAGE;

EID: 84887197254     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01174-13     Document Type: Article

References (35)

1. Cockburn WC, Drozdov SG. 1970. Poliomyelitis in the world. Bull. World Health Organ. 42:405-417.
2. Centers for Disease Control and Prevention. 2013. Progress toward eradication of polio-worldwide, January 2011-March 2013. Morb. Mortal. Wkly. Rep. 62:335-338.
3. Blomqvist S, Savolainen C, Laine P, Hirttio P, Lamminsalo E, Penttila E, Joks S, Roivainen M, Hovi T. 2004. Characterization of a highly evolved vaccine-derived poliovirus type 3 isolated from sewage in Estonia. J. Virol. 78:4876-4883.
4. Hovi T, Shulman LM, van der Avoort H, Deshpande J, Roivainen M, de Gourville EM. 2012. Role of environmental poliovirus surveillance in global polio eradication and beyond. Epidemiol. Infect. 140:1-13.
5. Centers for Disease Control and Prevention. 2013. Evaluating surveillance indicators supporting the Global Polio Eradication Initiative, 2011-2012. Morb. Mortal. Wkly. Rep. 62:270-274.
6. Minor PD, Almond JW. 2002. Poliovirus vaccines:molecular biology and immune response, p 381-390. In Semler BL, Wimmer E (ed), Molecular biology of picornaviruses. ASM Press, Washington, DC.
7. Sutter RW, Kew OM, Cochi SL, Aylward RB. 2013. Poliovirus vaccine-live, p 598-645. In Plotkin SA, Orenstein WA, Offit PA (ed), Vaccines, 6th ed. W. B. Saunders, London, United Kingdom.
8. Centers for Disease Control and Prevention. 2012. Update on vaccinederived polioviruses-worldwide, April 2011-June 2012. Morb. Mortal. Wkly. Rep. 61:741-746.
9. Jorba J, Campagnoli R, De L, Kew O. 2008. Calibration of multiple poliovirus molecular clocks covering an extended evolutionary range. J. Virol. 82:4429-4440.
10. Alexander JP, Jr, Gary HE, Jr, Pallansch MA. 1997. Duration of poliovirus excretion and its implications for acute flaccid paralysis surveillance: a review of the literature. J. Infect. Dis. 175:S176-S182.
11. Kew OM, Sutter RW, de Gourville EM, Dowdle WR, Pallansch MA. 2005. Vaccine-derived polioviruses and the endgame strategy for global polio eradication. Annu. Rev. Microbiol. 59:587-635.
12. Joffret ML, Jégouic S, Bessaud M, Balanant J, Tran C, Caro V, Holmblat B, Razafindratsimandresy R, Reynes J-M, Rakoto-Andrianarivelo M, Delpeyroux F. 2012. Common and diverse features of co-circulating type 2 and 3 recombinant vaccine-derived polioviruses isolated from patients with poliomyelitis and healthy children. J. Infect. Dis. 205:1363-1373.
13. Kew OM, Sutter RW, Nottay B, McDonough M, Prevots DR, Quick L, Pallansch M. 1998. Prolonged replication of a type 1 vaccine-derived poliovirus in an immunodeficient patient. J. Clin. Microbiol. 36:2893-2899.
14. Martín J, Dunn G, Hull R, Patel V, Minor PD. 2000. Evolution of the Sabin strain of type 3 poliovirus in an immunodeficient patient during the entire 637-day period of virus excretion. J. Virol. 74:3001-3010.
15. Martín J. 2006. Vaccine-derived poliovirus from long term excretors and the end game of polio eradication. Biologicals 34:117-122.
16. DeVries AS, Harper J, Murray A, Lexau C, Bahta L, Christensen J, Cebelinski E, Fuller S, Kline S, Wallace GS, Shaw JH, Burns CC, Lynfield R. 2011. Vaccine-derived poliomyelitis 12 years after infection in Minnesota. N. Engl. J. Med. 364:2316-2323.
17. Centers for Disease Control and Prevention. 2011. Update on vaccinederived polioviruses-worldwide, July 2009-March 2011. Morb. Mortal. Wkly. Rep. 60:846-850.
18. Shulman LM, Manor Y, Sofer D, Handsher R, Swartz T, Delpeyroux F, Mendelson E. 2006. Neurovirulent vaccine-derived polioviruses in sewage from highly immune populations. PLoS One 1:e69. doi:10.1371 /journal.pone.0000069.
19. Cernáková B, Sobotová Z, Rovnỳ I, Bláhova S, Roivainen M, Hovi T. 2005. Isolation of vaccine-derived polioviruses in the Slovak Republic. Eur. J. Clin. Microbiol. Infect. Dis. 24:438-439.
20. Roivainen M, Blomqvist S, Al-Hello H, Paananen A, Delpeyroux F, Kuusi M, Hovi T. 2010. Highly divergent neurovirulent vaccine-derived polioviruses of all three serotypes are recurrently detected in Finnish sewage. Euro Surveill. 15:pii/19566.
21. Burns C, Shaw J, Jorba J, Bukbuk D, Adu F, Gumede N, Iber J, Chen Q, Vincent A, Chenoweth P, Henderson E, Wannemeuhler K, Campagnoli R, Pate MA, Abanida E, Gasasira A, Shimizu H, Williams AJ, Kilpatrick D, Wassilak S, Tomori O, Pallansch M, Kew O. 2013. Multiple independent emergences of type 2 vaccine-derived polioviruses during a large outbreak in northern Nigeria. J. Virol. 87:4907-4922.
22. Bellmunt A, May G, Zell R, Pring-Akerblom P, Verhagen W, Heim A. 1999. Evolution of poliovirus type I during 5.5 years of prolonged enteral replication in an immunodeficient patient. Virology 265:178-184.
23. Yang C-F, Chen H-Y, Jorba J, Sun H-C, Yang S-J, Lee H-C, Huang Y-C, Lin T-Y, Chen P-J, Shimizu H, Nishimura Y, Utama A, Pallansch M, Miyamura T, Kew O, Yang J-Y. 2005. Intratypic recombination among lineages of type 1 vaccine-derived poliovirus emerging during chronic infection of an immunodeficient patient. J. Virol. 79:12623-12634.
24. Shahmahmoodi S, Parvaneh N, Burns C, Asghar H, Mamishi S, Tabatabaie H, Chen Q, Teimourian S, Gooya MM, Esteghamati A-R, Mousavi T, Yousefi M, Farrokhi K, Mashlool M, Kew O, Nategh R. 2008. Isolation of a type 3 vaccine-derived poliovirus (VDPV) from an Iranian child with X-linked agammaglobulinemia. Virus Res. 137:168-172.
25. Minin VN, Dorman KS, Fang F, Suchard MA. 2005. Dual multiple change-point model leads to more accurate recombination detection. Bioinformatics 21:3034-3042.
26. Suchard MA, Weiss RE, Dorman KS, Sinsheimer JS. 2003. Inferring spatial phylogenetic variation along nucleotide sequences:a multiple changepoint model. J. Am. Stat. Assoc. 98:427-437.
27. Cammack N, Phillips A, Dunn G, Patel V, Minor PD. 1988. Intertypic genomic rearrangements of poliovirus strains in vaccinees. Virology 167: 507-514.
28. Macadam AJ, Pollard SR, Ferguson G, Skuce R, Wood D, Almond JW, Minor PD. 1993. Genetic basis of attenuation of the Sabin type 2 vaccine strain of poliovirus in primates. Virology 192:18-26.
29. Ren R, Moss EG, Racaniello VR. 1991. Identification of two determinants that attenuate vaccine-related type 2 poliovirus. J. Virol. 65:1377-1382.
30. Westrop GD, Wareham KA, Evans DM, Dunn G, Minor PD, Magrath DI, Taffs F, Marsden S, Skinner MA, Schild GC, Almond JW. 1989. Genetic basis of attenuation of the Sabin type 3 oral poliovirus vaccine. J. Virol. 63:1338-1344.
31. Minor PD. 1990. Antigenic structure of picornaviruses. Curr. Top. Microbiol. Immunol. 161:121-154.
32. Yong PFK, Thaventhiran JED, Grimbacher B. 2011. "A rose is a rose is a rose," but CVID is not CVID common variable immune deficiency (CVID), what do we know in 2011? Adv. Immunol. 111:47-107.
33. Khetsuriani N, Prevots DR, Quick L, Elder ME, Pallansch M, Kew O, Sutter RW. 2003. Persistence of vaccine-derived polioviruses among immunodeficient persons with vaccine-associated paralytic poliomyelitis. J. Infect. Dis. 188:1845-1852.
34. Swofford DL. 2002. PAUP*. Phylogenetic analysis using parsimony (*and other methods). Version 4. Sinauer Associates, Sunderland, MA.
35. Toyoda H, Kohara M, Kataoka Y, Suganuma T, Omata T, Imura N, Nomoto A. 1984. Complete nucleotide sequences of all three poliovirus serotype genomes:implication for genetic relationship, gene function and antigenic determinants. J. Mol. Biol. 174:561-585.